Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
September 29, 2022 17:00 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
IMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
September 27, 2022 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief...